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Abstract
Objective:T oe stablish whether ad iet based on the usage of low-protein products for renal patients (LPP) is associated with
higher energy expenditure (EE) than af ree low-protein diet (NO-LPP) by calculating 24hE Eb yi ndirect calorimetryu sing an
electronic armband monitor.
Design:R andomized, cross-over, single-blind, pilot clinical trial performed comparing two different low-proteind ietary
regimens.
Subjects:F orty-twodayswith LPPand 42 dayswith NO-LPP regimen in six patientswith Parkinson’sdisease with levodopa.
Methods:M onitoring patient response to twod ifferent nutritional schemes through indirect calorimetry( armband), BMI,
Patient Global Improvement Scale.
Results:M ean total EE was 1731 ^ 265kcal/dayw ith NO-LPP vs.1 903 ^ 265kcal/day with LPP ( p ¼ 0.02).
Conclusions:T he usage of LPP increases EE and improves motor function in PD patients to ag reater extent than NO-LPP
dietaryr egimen. Calorie intake should be increased to prevent malnutrition in the long-term.
Sponsorship:F ondazione Grigioni per il Morbo di Parkinson.
Keywords: Parkinson’sd isease, diet, energye xpenditure, levodopa
Introduction
Parkinson’sd isease( PD) is ac ommon movement
disorder (worldwide prevalence: 3–4:1000), which
develops in the second half of life and is characterized
by bradykinesia, rigidity,r estingt remor and postural
instability (Zhang and Roman 1993; Quinn1 995).
The disorder is the result of an eurodegenerative
process that leads to the deatho fd opaminergic
neuronsi nt he substantia nigral ocatedi nt he
midbrain. The degenerative process is progressive
and inevitably leadst om ajor disability andm orbidity
associated with high healthcare expenditure (Schapira
1999).I ts etiology has not beene lucidated; it is
believedt hat the neuronald egeneration is due to a
number of environmentalf actors in genetically
susceptible subjects (Sherer et al. 2001).C urrent
therapy is symptomatic and consists in the replace-
mento fd opamine, the neurotransmitter that the
degenerated dopaminergic neurons no longerp ro-
duce, by administering either ap recursoro fd opamine
(levodopa) and/or other compounds that stimulate
dopaminergic receptors( dopamine agonists);l evo-
dopa is the most effectiver eplacement therapy and
ISSN 1028-415X print/ISSN 1476-8305 online q 2007 Informa UK Ltd.
DOI: 10.1080/10284150701414046
* MB designed the study.B Ma nd AgM were the experts in clinical nutrition responsible for anthropometrica ssessments, recruitment of
patients and interpretation of data. AV,C B, SEC and ArM weret he dieticians responsible for dietaryr egimens.C Sa nd AnM werer esponsible
for data managementa nd statistical analysis.G Pc ritically reviewed the protocol and manuscript.
Correspondence: M. Barichella, Parkinson Institute, Istituti Clinici di Perfezionamento,V ia Bignami, 1, 20126 Milano,I taly.
Tel: 39 057993222. Fax: 39 026433152. E-mail: barichella@parkinson.it; studiojh@usa.net
Nutritional Neuroscience,J une/August 2007; 10(3/4): 129–135soonero rl ater it is addedt ot he therapeutic regimeno f
all PD patients (Thanvi and Lo 2004). Also surgical
symptomatic therapy exists, namely deep brain stimu-
lation that consists in the stimulation of the damaged
neuronal circuits via implanted electrodes; its use is
conﬁned to advanced cases that no longer respond to
pharmacological therapy (Ahlskog 2001).
Most patients suffering from PD on treatment with
levodopa experiencef requentp ostprandial motor
blocks, i.e. periods of loss of efﬁcacyo fp harmaco-
logical treatment, associated with ar eduction in
quality of life (Thanvi andL o2 004).
The phenomenon has been ascribed also to the
intake of amino acidsd uring ap rotein-rich meal,
whichc ompete with levodopa, an eutral amino acid,
for the same carriersd uring absorption from the gut
and passage through the blood–brain barrier. Studies
have shown that al ow-protein meal at midday
improves motorﬂ uctuations and increases ON time
(Juncos et al. 1987; Rileya nd Lang1 988; Carter et al.
1989; Duarte et al. 1993; Simon et al. 2004).I ndeed,
al ow-protein diet is recommended by the guidelines
for the management of PD (Olanow et al. 2001;
Italian Neurological Society 2003).
In ap revious4 -month study (Barichella et al. 2006)
ad iet with ac ontrolled protein content( 0.8g/kg body
weight) was comparedw ith al ow-protein diet based
on the usage of low-protein food marketed for renal
patients. The results showed that consumption of
these foodsr educed daily time in OFF ande nabled a
reduction in pharmacological therapy in somec ases. A
reduction in bodyw eight during the ﬁrst two months
of consumptiono ft he specialf ood was observed. A
possible explanation was that the improvement in
motorf unction may haveb een associated with an
increase in energy consumptiont hatw as not
compensated by adequate caloryi ntake. This hypoth-
esis, however, was not clearly supported by evidence.
The objective of this study was to establish whether
al ow-protein diet basedo nt he usage of low-protein
food for renal patients( LPP) is associated with higher
energy expenditure (EE) than af ree low-protein diet
(NO-LPP) by calculating 24hE Eb yi ndirect
calorimetryu sing an electronica rmband monitor
(Jakicic et al. 2004).
Methods
This was ar andomized, cross-over, single-blind
clinical trial performed comparing two different low-
protein dietaryr egimens. It was performed in the
month of February 2006.
Six out of the 18 patients (30%) who took parti n
the previous study with low-protein food for renal
patientsw ere included (Barichella et al. 2006). The
ﬂow charto ft he study is shown in Table I.
They were PD patientsd iagnosed accordingt o
Brain BankC riteria (Hughese ta l. 1992) attending
theI CP ParkinsonI nstitute,o nt reatment with
levodopa,w ho were experiencing post-prandial
motorb lockso fa tl east 30min during the 5h after
the midday meal.
Thep atient population included threew omen and
threem en,m ediana ge 66 (50;76)y ears,m ean body
weight 64.3 ^ 11.1kg,b odym assi ndex( BMI)
24.1 ^  2.6kg/m
2 ,m edian duration of disease 21
(11;27) years, mean levodopa dosage 579 ^ 293 
mg/day;a ll patients were also receivingadopamine
agonist. No patients hadd ementia. Further detailsa re
provided in TableI I.
All patients were examined by ap hysician special-
ized in nutrition and were interviewed by ad ieticiana t
baseline, after aM iniM ental State examination had
been performed to exclude dementia. Theyw ere also
interviewed by ad ieticians ot hat she could prepare a
dietaryr egimen tailored to the tastes of the patient in
terms of sourceo fp rotein for the evening meal and
saucef or the pasta at midday.P atients were weighed
and their height was measured so that their BMI could
be calculated. Caloryr equirements were calculated on
the basis of basal metabolism estimated using the
formula of Harrisa nd Benedict (1919)a nd adding
20–30% according to reported physical activity.
Patients were randomized,u sing ar andomization
code prepared by theN utrition serviceo ft he Parkinson
Institute, to oneo ft wo low-proteind ietary regimens:
Table I. Study ﬂow-chart.
Group 1p atients 1-3-5 LPP CrossoverN O-LPP
Group 2p atients 2-4-6 NO-LPP LPP
Evaluations Day 0: baseline Day 7D ay 14: end of study
Body weight XX
Height X
Body mass index XX
Nutritional status XX
Mini Mental State examination X
Dietaryi nstructions XX
PGI XX
Diaryd ispensingX X
Diaryc ollectionX X
Armband XX X
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bodyw eight) achievedu sing low-protein food
marketed forr enal patients (LPP). Thesep roducts
(pasta,b read andm ilkt ob eu sedf or breakfast and
forl unch)w ereg iven to thep atient by ap hysician
specializedi nn utrition.T heir compositioni n
—a low-proteind ietary regimen (0.8–1g/kg ideal
body weight)a chievedb yd iminishing thec onsump-
tion of protein-richf ooda nd notr esorting to the
usageo fa ny specialk indo ff ood( NO-LPP).
Both dietaryr egimens provided on average the
intake of 31.2kcal/kg ideal body weight (range
30.0–34.0kcal/kg),withcaloriesspreadoutthroughout
the day;t hey were both in compliance with the
guidelines forhealthy nutritionintheItalian population
(Guidelinesf or healthyn utrition 2003).
Patients were given detailed instructions so that
directc omparisons between low-protein food and
common food could be made (seee xample of
1800kcal diet in Table III showing the difference
in terms of protein content). Each dietw as followed
for 7d ays before assessments.T he content of LPPand
common foodsu sedf or patient dietaryr egimens in
terms of amino acidsc ompeting with levodopa for
absorption is provided in Tables IVAa nd IVB.
Table II. Patient population details.
Patient Sex Age Yearso fd isease kcal/day: 1st weekk cal/day: 2nd week
Weight
(kg)
Height
(cm)
BMI
(kg/m
2 )
Levodopa dose
(mg/day)
1F 76 21 1523 with LPP 1550 NO LPP 59 151 25.9 450
2M 69 11 1795 NO LPP 1800 with LPP 83 172 28.1 1000
3M 58 27 1800 with LPP 1800 NO LPP 67 164 24.9 500
4F 64 23 1660 NO LPP 1650 with LPP 54 159 21.4 250
5M 50 11 2250 with LPP 2250 NO LPP 69 177 22.1 400
6F 68 13 1800 NO LPP 1800 with LPP 54 156 22.2 875
Table III. Ac omparison between dietaryr egimen of 1800kcal with and without LPP products.
Diet 1800kcal with LPP Diet 1800kcal NO LPP
Proteins 10.1% Proteins 13.9%
Lipids 28.7% Lipids 26.7%
Carbohydrates 61.2% Carbohydrates 59.4%
Breakfast
Teao rc offee S.Q. Teao rc offee S.Q.
Jamg 25 Jamg 25
Biscuits LPP g5 0B iscuits g5 0
Lunch
Pasta LPP g8 0P asta g8 0
Vegetables S.Q. Vegetables S.Q.
Oil g1 5O il g1 5
Fruits g1 50 Fruits g1 50
Snack
Biscuits LPP g5 0B iscuits g5 0
Dinner
Bread g5 0B read g5 0
Vegetables S.Q. Vegetables S.Q.
Oil g1 5O il g1 5
Fruits g1 50 Fruits g1 50
MondayM eat g1 50 MondayM eat g1 50
Tuesday Cheese g1 00 Tuesday Cheese g1 00
Wednesday Fish g2 50 WednesdayF ish g2 50
Thursday Twoe ggs Thursday Twoe ggs
Friday Fish g2 50 Friday Fish g2 50
SaturdayL egumes g1 00 SaturdayL egumes g1 00
SundayH AM g1 00 SundayH AM g1 00
Diet 1800kcal with LPP Diet 1800kcal with NO LPP
Proteins (g) Percentage of protein (percentage
total kcal)
Protein (g) Percentage of protein (percentage
of total kcal)
Breakfast 0.50 0.16 3.55 0.80
Lunch 4.75 1.00 16.23 3.60
Snack 0.50 0.16 2.51 0.61
Dinner 39.72 8.82 39.72 8.82
Total value4 5.49 10.10 62.01 13.83
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dietaryr egimeno ft he patient, who was instructed not
to mention it to the examiners.
Patients were givens tudy diaries andw ere
instructed to write down the following information
everyd ay: hourso fs leep; waking hoursi nO N, i.e.
timesw henm edication wasw orking andm otor
symptomsa re controlled (with and without dyskine-
sias) andh oursi nO FF,i .e. times when the medication
was notw orking and symptoms reappeared; time of
antiparkinsonian drug intake; time of meals; any
deviations from the dietaryr egimen.
An armband (Bodymedia Sensewear Pro2)w as
positioned on the right triceps of the patients for the
whole 14 dayperiod (24hper day)of the study,s ot hat
it could measure EE continuously.T he SenseWear
Pro Armbande (Body Media, Pittsburgh, PA)i sa
newly developed commercially available device to
assess EE. It has alreadyb een extensivelyu sed for
researchp urposesa nd its use has beenv alidated not
only for usage in sports medicine (Fruin and Rankin
2004) and in particular environments,s uch as under
water, but also during normal daily activity (Mignault
et al 2005; Levine and Foster 2005).T he device is
worno nt he right upper armo ver the triceps muscle
and monitorsv arious physiological and movement
parameters.D ataf rom av ariety of parameters
including heat ﬂux,a ccelerometry,g alvanic skin
response, skin temperature, near-bodyt emperature
and demographic characteristics (gender, age, height
and body weight) are used to estimateE Eu tilizing
proprietarye quations developed by the manufacturer.
Due to its lightness and wearability,t he armband
monitor is particularly suitable for continuous patient
monitoring fors everal days.T he software data
analysis was carried out at the end of eacho ft he
7d ays of the dietaryr egimenp eriod.
At the end of each dietaryr egiment he patient global
improvement (PGI) questionnaire was given to the
patients, who completed it by themselves. The PGI
serveda sa ni ndependent, yet patient-based assess-
mento fatreatment effect.
The primary endpoint was EE. The secondary
endpoints were: 24hO FF time, 24hO Nt ime with
and without dyskinesias.
The statistical analysis compared data related to
days on balanced diet with data related to days on LPP
diet using ANOVA.
Diaryc ards were coded with the number of the
patient andt he allocated sequence (AB or BA). The
person whoa nalyzed the data was blind to sequence.
Results
All six patients completed the study as per protocol
and provided 84 valid diaries, 42 with LPP and 42
with NO-LPPr egimen.
Diaryr esults
Twenty-four hours OFF time was signiﬁcantly shorter
after LPP diet than after NO-LPP diet (3.5hv s. 5h,
p ¼ 0.01); 24hd yskinetic ON time was signiﬁcantly
longer afterL PP diet (6hv s. 4.5h, p ¼ 0.04)
(Figure 1).
Armband results
The armband was wornb yt he patients for 98% of the
time in both the evaluation periods associated with the
two nutritional schemes.
The daily hourso fs leep were similar in the two
groups (7.68 ^ 1.94 with NO-LPPv s. 8.02 ^ 2.2h
with LPP). These results are consistent with the
sleeph ours estimated from the patient diarya nalysis.
An increase in total EE of about1 0% was noticed
for the LPP dietaryr egimen comparedt ot he NO-
LPP diet: mean total EE was 1731 ^ 265kcal/day
with NO-LPPd iet vs. 1903 ^ 265kcal/day with LPP
( p ¼ 0.02). Also the time spent in physical activity was
longerw ith LPP than with NO-LPPd iet (1.75 ^ 1.33
vs. 1.38 ^ 1.32h; p ¼ 0.05).
PGI results
According to PGI questionnaires, all patients
expressed ab eneﬁtw ith LPP regimen( verym uch
better n ¼ 2, muchb etter n ¼ 4) while no beneﬁto r
worsening were expressed with the NO-LPPd iet.
Table IVA. Ac omparison in protein content between LPP and common foods.
LPP products Proteins (g/100g) kcal/100gC ommon foods Proteins (g/100g) kcal/100g
Breakfast
Semi-sweetb iscuits , 14 49 Semi-sweet biscuits 6.6 418
Plain biscuits , 1.35 488.5 Plain biscuits 7.4 493
Wafers , 1.2 539.5 Wafers 7.1 454
Lunch
Breadsticks (grissini) , 1.4 419 Breadsticks( grissini) 12.3 433
Toasted bread , 1.6 399 Rice 73 62
Melba toast , 14 21 Melba toast 11.3 410
Pasta , 0.7 354 Pasta 10.8 356
M. Barichella et al. 132Discussion
This study shows that the LPPd ietaryr egimeni s
associated with as igniﬁcant increase in EE in
ﬂuctuating PD patients, as measured by the armband.
This ﬁnding is consistent with the additional evidence
of improvement in motor function in such patients,
expressed as as igniﬁcant reduction in 24hO FF time,
according to both armband and patient diaryd ata.
Theo nlyd ifferenceb etween thet wo low-protein
dietaryr egimens( oneu sing low-proteinf oodf or renal
patientsandthe otherbeing af reelow-proteindiet)w as
them idday meal proteinc ontent (withl ower protein
contentf or thel ow-protein productf oodn utritional
scheme); thep rotein intake in thee vening meal wast he
same.I ta ppears that thei ncreasei nE Ea nd greater
improvement in motorf unctionw ithL PP wasd ue to
better absorptiono fl evodopaa tm idday,l essh indered
by lowerp rotein intake.C alorie intake andh ours of
sleepw eres imilar in thet wo groupsa nd should not
have inﬂuencedr esults.F urthermore,t hese results
suggest that thee vening meal doesn ot play an
importantr olei nd eterminingm otor performance.
An additional ﬁnding wast he increase in ON periods
with dyskinesias, accordingt ot he patientd iary data.
Theo utputd atao ft he armbandd id note nableu st o
addresst he issueo fw hether theh igherE Ec omes from
an increase in physiologicalp hysicala ctivityo ri n
dyskinesias. Accurate tuning of thea lgorithm elaborat-
ingt he accelerometers ignalsshouldbeimplementedt o
be able to distinguishb etween thet wo in subsequent
studies. In anyc ase, thei mprovement in PGIs uggests
that thei ncreasei nd yskinesias didn ot counteract the
beneﬁt of improved motorf unction. Indeed,d yskine-
sias do nota lwaysc ause disability anda ctually show
that levodopa is beinga bsorbeda nd is effective. In
addition,i ti sw ellk nown that ﬂuctuating patients
(motor ﬂuctuationsw erea ni nclusion criterion)p refer
dyskinesiast oO FF episodes,w hich were another
inclusionc riterion, as patients hadt oh avep ostprandial
OFFe pisodes( Palmer et al.2 000).
The improvements achieved in OFF and ON time
are consistent with those recordedi nt he previous
study (Barichella et al. 2006), in which ad iet with a
controlled protein content( 0.8g/kgb ody weight) was
compared with al ow-protein diet basedo nt he usage
of low-protein food marketed for renal patients.
Ak ey issue in this study is the subjectivity of the
patient diaryd ata and the novelty of the armband used
for the measurement of the primarye ndpoint, EE.
The use of patient diariesi sagenerally accepted
method by regulatoryauthorities for the assessment of
medicinal products (EMEA,C PMP/EWP/563/1995).
Sensewear Pro2 has alreadyb een extensively used for
researchp urposesa nd its use has been validated not
only for usage in sports medicine and in particular
environments, such as under water, but also during
normal daily activity (Mignault et al. 2005; Levinea nd
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Diet and motorf unction in Parkinsonian 133Foster 2005).C onsequently,i ts measurement mayb e
considered to be reliable. At present no alternative
methods and devices for medium-termd aily EE
monitoring are available.
It would haveb een useful to measuret he blood
levels of levodopa and of the amino acidst hat compete
with the drug,a st his would enable us to understand
where the competition occurs( at the blood–intestine
and/or blood–brain barrier). However, the primary
objective of ours tudy wasd ifferent,n amelyt o
establish whether the body weight loss thato ccurs
during LPP consumption is due to greater EE or not;
our secondaryo bjectives were to establish whether the
ON periods associatedw ith dyskinesias increase and
whether the evening meal has an inﬂuence or not. We
havea lready planned anothers tudy focusing on amino
acid/levodopa competition, in whichb lood levelsw ill
be measured.
Thus, the ﬁndings of this study suggest that the
consumption of LPP for renal patients is as imple way
to improvet he therapeutic efﬁcacyo fl evodopa, which
does not appear to havea ny important drawbacks, as
dyskinesias are not am ajor problem and malnutrition
can easily be prevented by increasing caloryi ntake. Its
rationalei sb asedo nt he recommendation to reduce
protein intake at midday in order to prevent their
interference with levodopa absorption associated with
postprandial OFF episodes, which is includedi n
international guidelines for the management of PD
(Olanow 2001; Italian Neurological Society 2003).
Indeed,P Dp atients shouldc onsume these products,
whichh aveb een on the market for more thana
decade,o nly at midday and nott hroughout the day as
renal patients( Kopple, 2001),s ot he overall risk of
malnutrition in PD patientsi sl ower than in renal
patients.
In conclusion, the consumptiono fr enal LPP is
associatedwith animprovementinmotorfunctionand
an increase in EE in PD patients to ag reater extent
than NO-LPPd ietaryr egimen alone. The increase in
EE shouldb et akeni nto account for the overall
management of PD patients: calorie intake should be
increased to prevent malnutrition in the long-term.
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